Application of AI on cholangiocarcinoma

Jianhao Huang; Xuesong Bai; Yanyu Qiu; Xiaodong He

doi:10.3389/fonc.2024.1324222

Application of AI on cholangiocarcinoma

Front Oncol. 2024 Jan 29:14:1324222. doi: 10.3389/fonc.2024.1324222. eCollection 2024.

Authors

Jianhao Huang^#¹, Xuesong Bai^#¹, Yanyu Qiu^#¹, Xiaodong He¹

Affiliation

¹ Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.

^# Contributed equally.

Abstract

Cholangiocarcinoma, classified as intrahepatic, perihilar, and extrahepatic, is considered a deadly malignancy of the hepatobiliary system. Most cases of cholangiocarcinoma are asymptomatic. Therefore, early detection of cholangiocarcinoma is significant but still challenging. The routine screening of a tumor lacks specificity and accuracy. With the application of AI, high-risk patients can be easily found by analyzing their clinical characteristics, serum biomarkers, and medical images. Moreover, AI can be used to predict the prognosis including recurrence risk and metastasis. Although they have some limitations, AI algorithms will still significantly improve many aspects of cholangiocarcinoma in the medical field with the development of computing power and technology.

Keywords: artificial intelligence; cholangiocarcinoma (CCA); diagnosis; machine learning (ML); prognosis.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CAMS) Initiative for Innovative Medicine (Grant No. 2021-I2M-1-022) and National High Level Hospital Clinical Research Funding (Grant No. 2022-PUMCHB-003).